Suchergebnisse

Biogeographical diversity is central to the trophic ecology of predators. Understanding the biogeographical trophic patterns of generalist predators, such as the red fox Vulpes vulpes, is particularly challenging because of their wide distributions, broad trophic spectra and high ecological plasticity, which often generate conflicts with humans. We reviewed 55 studies from the Iberian Peninsula concerning the diet of the red fox to describe its trophic patterns from a biogeographical perspective. We considered the frequency of occurrence of seven food groups and characterized each study site according to environmental variables. We tested relationships between geographical variables and each food group independently, and assessed the consumption of lagomorphs in relation to the other food groups. We also tested the relationships between trophic diversity, the main food groups, latitude and altitude, and finally investigated changes in the consumption of all food groups in relation to habitat type and seasonality. We found a latitudinal pattern in the diet of the red fox, which was characterized by a greater consumption of lagomorphs and invertebrates in southern areas, and a higher intake of small mammals and fruits/seeds in northern regions. Additionally, the consumption of invertebrates increased from east to west, while fruit/seed consumption increased from west to east. Consumption of lagomorphs decreased, and of small mammals increased, with altitude. Trophic diversity was not associated with geographical variables. The intake of lagomorphs and small mammals was greatest in Mediterranean scrub and forest, respectively. Reptiles and invertebrates were consumed mostly during summer; fruits/seeds in autumn. Iberian red foxes show variation in their feeding habits associated with environmental variables, which are in turn associated with the availability of their main prey. Foxes select rabbits where they are abundant, and feed on small mammals and fruits/seeds where lagomorphs are scarce. ; M. Delibes-Mateos currently holds a Juande la Cierva research contract awarded by the Ministerio de Ciencia e Innovación and the European Social Fund. C. Ferreira was supported by a PhD grant (Ref. SFRH/BD/22084/2005) funded by the Fundação para a Ciência e Tecnologia of the Ministério da Ciência, Tecnologia e Ensino Superior, Portuguese government. Financial support for the study was provided by the Spanish MICINN Project CGL2009-10741 from Spanish Plan Nacional de I+D and FEDER funds. ; Peer Reviewed

Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A. Here, we show that plitidepsin distributes preferentially to lung over plasma, with similar potency against across several SARS-CoV-2 variants in preclinical studies. Simultaneously, in this randomized, parallel, open-label, proof-of-concept study (NCT04382066) conducted in 10 Spanish hospitals between May and November 2020, 46 adult hospitalized patients with confirmed SARS-CoV-2 infection received either 1.5 mg (n = 15), 2.0 mg (n = 16), or 2.5 mg (n = 15) plitidepsin once daily for 3 d. The primary objective was safety; viral load kinetics, mortality, need for increased respiratory support, and dose selection were secondary end points. One patient withdrew consent before starting procedures; 45 initiated treatment; one withdrew because of hypersensitivity. Two Grade 3 treatment-related adverse events were observed (hypersensitivity and diarrhea). Treatment-related adverse events affecting more than 5% of patients were nausea (42.2%), vomiting (15.6%), and diarrhea (6.7%). Mean viral load reductions from baseline were 1.35, 2.35, 3.25, and 3.85 log10 at days 4, 7, 15, and 31. Nonmechanical invasive ventilation was required in 8 of 44 evaluable patients (16.0%); six patients required intensive care support (13.6%), and three patients (6.7%) died (COVID-19-related). Plitidepsin has a favorable safety profile in patients with COVID-19. ; This work was supported by grants from the Government of Spain (PIE_INTRAMURAL_ LINEA 1 - 202020E079; PIE_INTRAMURAL_CSIC-202020E043). The research of CBIG consortium (constituted by IRTA-CReSA, BSC, & IrsiCaixa) is supported by Grifols pharmaceutical. We also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com). N Izquierdo-Useros has nonrestrictive funding from PharmaMar to study the antiviral effect of Plitidepsin. NJ Krogan was funded by grants from the National Institutes of Health (P50AI150476, U19AI135990, U19AI135972, R01AI143292, R01AI120694, and P01AI063302); by the Excellence in Research Award (ERA) from the Laboratory for Genomics Research (LGR), a collaboration between the University of California, San Francisco (UCSF), University of California, Berkley (UCB), and GlaxoSmithKline (GSK) (#133122P); by the Roddenberry Foundation, and gifts from QCRG philanthropic donors. This work was supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement #HR0011-19-2-0020. The views, opinions, and/or findings contained in this material are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government. This research was partly funded by Center for Research for Influenza Pathogenesis and Transmission (CRIPT), a National Institute of Allergy and Infectious Diseases (NIAID) supported Center of Excellence for Influenza Research and Response (CEIRS, contract # 75N93021C00014), by DARPA grant HR0011-19-2-0020, by supplements to NIAID grants U19AI142733, U19AI135972, and DoD grant W81XWH-20-1-0270, and by the generous support of the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384)), and anonymous donors to A García-Sastre. S Yildiz received funding from a Swiss National Foundation Early Postdoc Mobility fellowship (P2GEP3_184202). ; Peer reviewed